The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
Open accessAbstract
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8 + T cells. Although PD-1 and TIGIT are thought to regulate different costimulatory receptors (CD28 and CD226), effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. CD226 expression associated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-PD-L1 antibody atezolizumab. CD226 and CD28 were co-expressed on NSCLC infiltrating CD8 + T cells poised for expansion. Mechanistically, PD-1 inhibited phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD); TIGIT's ICD was dispensable, with TIGIT restricting CD226 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of CD226 signaling, and optimal anti-tumor CD8 + T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedFiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Advanced methods of microscope control using μManager software
D. Edelstein, A., A. Tsuchida, M., Amodaj, N., Pinkard, H., D. Vale, R., & Stuurman, N. (2014) · Journal of Biological Methods · doi:10.14440/jbm.2014.36 · Cited by 1,909
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Self-citationSiddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534
Yu, X., Harden, K., C Gonzalez, L., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., et al. (2009) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,491
Self-citationThe Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Utzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.021 · Cited by 1,085
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.012 · Cited by 955
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 817
Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Self-citationCD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 656
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Wu, T., Ji, Y., Moseman, E. A., Xu, H. C., Manglani, M., Kirby, M., Anderson, S. M., Handon, R., Kenyon, E., Elkahloun, A., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai8593 · Cited by 627
Self-citationCutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Joller, N., Hafler, J. P., Brynedal, B., Kassam, N., Spoerl, S., Levin, S. D., Sharpe, A. H., & Kuchroo, V. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003081 · Cited by 581
The TIGIT/CD226 Axis Regulates Human T Cell Function
Lozano, E., Dominguez-Villar, M., Kuchroo, V., & Hafler, D. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103627 · Cited by 476
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459
Self-citationTIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2016.10.002 · Cited by 415
Self-citationPeters, S., Gettinger, S., Johnson, M. L., Jänne, P. A., Garassino, M. C., Christoph, D., Toh, C. K., Rizvi, N. A., Chaft, J. E., Carcereny Costa, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 400
Gilfillan, S., Chan, C. J., Cella, M., Haynes, N. M., Rapaport, A. S., Boles, K. S., Andrews, D. M., Smyth, M. J., & Colonna, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081752 · Cited by 361
Liu, S., Zhang, H., Li, M., Hu, D., Li, C., Ge, B., Jin, B., & Fan, Z. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.141 · Cited by 342
Brummelman, J., Mazza, E. M. C., Alvisi, G., Colombo, F. S., Grilli, A., Mikulak, J., Mavilio, D., Alloisio, M., Ferrari, F., Lopci, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180684 · Cited by 334
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
Tissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVR
Stanietsky, N., Rovis, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J., Jonjic, S., & Mandelboim, O. (2013) · European Journal of Immunology · doi:10.1002/eji.201243072 · Cited by 263
Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule
Shibuya, K., Lanier, L. L., Phillips, J. H., Ochs, H. D., Shimizu, K., Nakayama, E., Nakauchi, H., & Shibuya, A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80136-3 · Cited by 260
Li, M., Xia, P., Du, Y., Liu, S., Huang, G., Chen, J., Zhang, H., Hou, N., Cheng, X., Zhou, L., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572420 · Cited by 259
Shibuya, K., Shirakawa, J., Kameyama, T., Honda, S.-I., Tahara-Hanaoka, S., Miyamoto, A., Onodera, M., Sumida, T., Nakauchi, H., Miyoshi, H., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030958 · Cited by 250
Rodriguez-Abreu, D., Johnson, M. L., Hussein, M. A., Cobo, M., Patel, A. J., Secen, N. M., Lee, K. H., Massuti, B., Hiret, S., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9503 · Cited by 244
Stengel, K. F., Harden-Bowles, K., Yu, X., Rouge, L., Yin, J., Comps-Agrar, L., Wiesmann, C., Bazan, J. F., Eaton, D. L., & Grogan, J. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120606109 · Cited by 217
Self-citationMemory CD8+ T cell responses to cancer
Han, J., Khatwani, N., Searles, T. G., Turk, M. J., & Angeles, C. V. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101435 · Cited by 216
Tissue-Resident Memory T Cells in Cancer Immunosurveillance
Park, S. L., Gebhardt, T., & Mackay, L. K. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.002 · Cited by 193
Corgnac, S., Malenica, I., Mezquita, L., Auclin, E., Voilin, E., Kacher, J., Halse, H., Grynszpan, L., Signolle, N., Dayris, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100127 · Cited by 182
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Balança, C.-C., Salvioni, A., Scarlata, C., Michelas, M., Gomez‐Roca, C., Gomez‐Roca, C., Sarradin, V., Tosolini, M., Valle, C., Pont, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142513 · Cited by 173
Braun, M., Aguilera, A. R., Sundarrajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L. G., Meza Guzman, L. G., Li, K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.010 · Cited by 171
Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., Gurer, C., Wei, J., Ramos, I., Wu, Q., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat7061 · Cited by 167
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
Dixon, K. O., Schorer, M., Nevin, J., Etminan, Y., Amoozgar, Z., Kondo, T., Kurtulus, S., Kassam, N., Sobel, R. A., Fukumura, D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700407 · Cited by 166
Weulersse, M., Asrir, A., Pichler, A., Lemaitre, L., Braun, M., Carrié, N., Joubert, M.-V., Moine, M. L., Souto, L. D., Gaud, G., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.006 · Cited by 162
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
Banchereau, R., Chitre, A. S., Scherl, A., Wu, T. D., Patil, N. S., de Almeida, P. E., Kadel, E. E., Madireddi, S., Au‐Yeung, A., Takahashi, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002231 · Cited by 161
Self-citationIn vitro membrane reconstitution of the T-cell receptor proximal signaling network
Hui, E., & Vale, R. D. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2762 · Cited by 144
Self-citationTIGIT signaling restores suppressor function of Th1 Tregs
Lucca, L. E., Axisa, P., Singer, E. R., Nolan, N. M., Dominguez‐Villar, M., & Hafler, D. A. (2019) · JCI Insight · doi:10.1172/jci.insight.124427 · Cited by 141
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 141
Self-citationCD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential
Konduri, V., Oyewole-Said, D., Vazquez‐Perez, J., Weldon, S. A., Halpert, M. M., Levitt, J. M., & Decker, W. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613204 · Cited by 121
Recruiting T cells in cancer immunotherapy
Yost, K. E., Chang, H. Y., & Satpathy, A. T. (2021) · Science · doi:10.1126/science.abd1329 · Cited by 109
Waight, J. D., Chand, D. S., Dietrich, S., Gombos, R. B., Horn, T. L., Gonzalez, A. M., Manrique, M. L., Swiech, L. J., Morin, B. M., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 108
Chiang, E. Y., de Almeida, P. E., Nagata, D. D. A., Bowles, K. H., Du, X., Chitre, A. S., Banta, K. L., Kwon, Y. C., McKenzie, B. S., Mittman, S., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948405 · Cited by 107
Self-citationBéziat, V., Rapaport, F., Hu, J., Titeux, M., Bonnet des Claustres, M., Bourgey, M., Griffin, H., Bandet, É., Ma, C. S., Sherkat, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.004 · Cited by 95
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Jin, H., Ko, M., Choi, D., Kim, J. H., Lee, D.-H., Kang, S.-H., Kim, I., Lee, H. J., Choi, E. K., Kim, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0877 · Cited by 90
Manes, T. D., & Pober, J. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002835 · Cited by 76
Ralston, K. J., Hird, S. L., Zhang, X., Scott, J. L., Jin, B., Thorne, R. F., Berndt, M. C., Boyd, A., & Burns, G. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401040200 · Cited by 75
Du, X., de Almeida, P. E., Manieri, N., Nagata, D. D. A., Wu, T. D., Bowles, K. H., Arumugam, V., Schartner, J. M., Cubas, R. A., Mittman, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814052115 · Cited by 67
Self-citationShah, N. H., Löbel, M., Weiss, A., & Kuriyan, J. (2018) · eLife · doi:10.7554/elife.35190 · Cited by 63
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Xu, X., Masubuchi, T., Cai, Q., Zhao, Y., & Hui, E. (2021) · eLife · doi:10.7554/elife.74276 · Cited by 59
Self-citationResident Memory T Cells and Their Effect on Cancer
Craig, D. J., Creeden, J. F., Einloth, K. R., Gillman, C. E., Stanbery, L., Hamouda, D., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Vaccines · doi:10.3390/vaccines8040562 · Cited by 30
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
Yang, F., Zhao, L., Wei, Z., Yang, Y., Liu, J., Li, Y., Tian, X., Liu, X., Lü, X., & Sui, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901413 · Cited by 26
Cited by
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Self-citationTherapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Metadata
- Authors
- Banta, K. L., Xu, X., Chitre, A. S., Au-Yeung, A., Takahashi, C., O’Gorman, W. E., Wu, T. D., Mittman, S., Cubas, R., Comps-Agrar, L., Fulzele, A., Bennett, E. J., Grogan, J. L., Hui, E., Chiang, E. Y., & Mellman, I.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 55
- Issue
- 3
- Pages
- 512-526.e9
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W4220788548
- Cited by
- 370
- References
- 68
- FWCI
- 26.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.